Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02917369

Integrative Analysis of Large-cell Lung Cancer

Integrative analysis of LCLC

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasm Metastasis Neoplasms Neoplasms by Site Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ganzhou City People's Hospital, Ganzhou, Jiangxi, China

Loading trial locations.

About this study

The investigators will analyzed proteomes of paired normal lung tissues and LCLC with or without liver metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary LCLC carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≤ 75 years with histologically proven LCLC
  • No severe major organ dysfunction
  • World Health Organization (WHO) performance status of 0 or 1
  • No prior cancer chemotherapy

Exclusion criteria

  • Age ≥ 76
  • Severe major organ dysfunction
  • WHO performance status of >1
  • Prior cancer chemotherapy

Treatment and study plan

Normal lung tissue

Other

The investigators will extract total protein, DNA and RNA from LCLC patients.

Primary outcomes

  1. 5 years overall survival

    Time frame: 5 years

Secondary outcomes

  1. 5 years disease-free survival

    Time frame: 5 years

Study contacts

Contact information is provided by the study sponsor or research team.

Da Fu, PhD

CONTACT

[email protected]

00-86-21-66301604

Sponsors and collaborators

Lead sponsor

Shanghai 10th People's Hospital

Other

Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

Registry information

Official study title

Integrative Analysis of Large-cell Lung Carcinoma

Acronym: LCLC

Important dates

Study start
2016
Primary completion
2026
Study completion
2026
First posted
Sep 28, 2016
Registry last updated
Sep 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.